6.3 Women's Health: Contraception, Menopause & Teratogenicity

Women's Health: Contraception, Menopause & Teratogenicity

Executive Summary: Outpatient women's health encompasses critical pharmacotherapy decisions across the reproductive lifespan—from precision contraceptive selection and emergency postcoital management to the delicate balance of menopausal hormone therapy and the vigilant prevention of medication-induced teratogenicity. For the Board Certified Ambulatory Care Pharmacist (BCACP), mastery of the CDC United States Medical Eligibility Criteria (US MEC) for Contraceptive Use, the physiological boundaries of menopausal hormone therapy (the "uterus status rule" and "timing hypothesis"), and the pharmacokinetics of milk-plasma drug transfer (LactMed / RID <10%) is essential for safeguarding maternal and fetal outcomes.

1. CDC US Medical Eligibility Criteria (US MEC) & Combined Hormonal Contraceptive Safety

The Centers for Disease Control and Prevention (CDC) publishes the United States Medical Eligibility Criteria for Contraceptive Use (US MEC), providing an evidence-based safety framework that categorizes contraceptive methods across specific medical conditions into four distinct tiers:

+-----------------------------------------------------------------------------+
|                   CDC US MEC FOUR-TIER CLASSIFICATION SYSTEM                |
+------------+----------------------------------------------------------------+
| Category 1 | No restriction for the use of the contraceptive method.       |
+------------+----------------------------------------------------------------+
| Category 2 | Advantages of using the method generally outweigh the risks.   |
+------------+----------------------------------------------------------------+
| Category 3 | Theoretical or proven risks usually outweigh the advantages.   |
|            | (Method not recommended unless other methods unavailable)      |
+------------+----------------------------------------------------------------+
| Category 4 | UNACCEPTABLE HEALTH RISK (Absolute Contraindication).          |
|            | The method MUST NOT be used under any circumstance.           |
+------------+----------------------------------------------------------------+

Category 4 (Absolute Contraindications) for Combined Hormonal Contraceptives (CHCs)

Combined Hormonal Contraceptives contain an estrogen (ethinyl estradiol, estradiol valerate, estetrol) plus a progestin, delivered via oral tablets (COCs), transdermal patch (Xulane, Twirla), or vaginal ring (NuvaRing, Annovera). Estrogen promotes hepatic synthesis of clotting factors (fibrinogen, Factor VII, Factor VIII, Factor X) and downregulates antithrombin III, increasing thromboembolic risk.

2. Progestin-Only Modalities & Long-Acting Reversible Contraception (LARCs)

Progestin-only contraceptives and LARCs avoid the thrombogenic risks of ethinyl estradiol, making them the preferred first-line options for women with cardiovascular, thromboembolic, or migraine-with-aura contraindications.

Progestin-Only Pills (POPs)

1. Norethindrone 0.35 mg (Micronor, Camila, Nor-QD):
   • Mechanism: Thickens cervical mucus to prevent sperm penetration (within 2–4 hours of ingestion) and alters endometrium; suppresses mid-cycle ovulation in only ~50% of menstrual cycles.
   • The Strict 3-Hour Adherence Window: Norethindrone has an exceptionally short half-life. If a dose is taken more than 3 hours late (or missed entirely), the cervical mucus barrier degrades. The patient must take the missed pill immediately, take the next pill at the regular time, and use a backup barrier method (or abstain) for at least 48 hours.
2. Drospirenone 4 mg (Slynd):
   • Regimen: 24 active tablets followed by 4 inert tablets. Consistently inhibits ovulation.
   • 24-Hour Missed-Pill Window: Offers a forgiving 24-hour window similar to COCs.
   • Electrolyte Caution: Drospirenone is a spironolactone analogue with anti-mineralocorticoid activity. Monitor serum potassium in patients taking concomitant potassium-sparing medications (ACEis, ARBs, MRAs, potassium supplements).

Depot Medroxyprogesterone Acetate (DMPA / Depo-Provera)

• Administration: 150 mg deep IM (gluteal/deltoid) or 104 mg SubQ every 12 to 13 weeks (with a 2-week grace window up to 15 weeks). Highly effective (>99% typical use).
• Mechanism: Completely suppresses pituitary LH and FSH surges, abolishing ovulation.
• FDA Boxed Warning — Loss of Bone Mineral Density (BMD): Suppresses ovarian estradiol synthesis, inducing a hypoestrogenic state that causes reversible bone mineral density loss. Package labeling recommends limiting continuous use to 2 years unless other contraceptive methods are inadequate. Counsel patients to ensure adequate calcium (1,000–1,200 mg/day) and vitamin D (600–1,000 IU/day) intake and engage in weight-bearing exercise.
• Clinical Considerations: Substantial weight gain (average 3–5 kg), progressive amenorrhea (~50% at 1 year, ~70% at 2 years), and a delayed return of fertility (median 10 months, ranging up to 18 months post-discontinuation).

Long-Acting Reversible Contraceptive (LARC) Devices

3. Emergency Contraception (EC): Modalities, Weight Cutoffs & Counseling

Emergency contraception prevents unintended pregnancy after unprotected sexual intercourse or contraceptive failure (e.g., condom rupture, missed oral pills). Emergency contraceptives act exclusively prior to fertilization and implantation by inhibiting or delaying the luteinizing hormone (LH) surge and follicular rupture. They are NOT abortifacients and have zero efficacy once implantation has occurred.

Comparison of Emergency Contraceptive Modalities

Patient Counseling Pearls for Post-EC Nausea & Vomiting

• If vomiting occurs within 2 to 3 hours of taking an oral EC dose (levonorgestrel or ulipristal), the dose must be repeated.
• Routine administration of prophylactic antiemetics (e.g., meclizine, dimenhydrinate) may be considered, though oral levonorgestrel and ulipristal cause significantly less nausea/emesis than historical Yuzpe regimen high-dose estrogen pills.

4. Menopause Hormone Therapy (MHT) & Vasomotor Management

Menopausal transition is marked by ovarian follicular depletion, leading to declining estradiol levels and compensatory elevation of pituitary FSH and LH. Clinical indications for Menopausal Hormone Therapy (MHT) include moderate-to-severe vasomotor symptoms (VMS: hot flashes, night sweats), symptoms of Genitourinary Syndrome of Menopause (GSM / vulvovaginal atrophy), and prevention of postmenopausal osteoporosis in women with elevated fracture risk and intolerance to non-hormonal agents.

The "Uterus Status Rule" in Systemic MHT

+-----------------------------------------------------------------------------+
|                        THE SYSTEMIC MHT UTERUS STATUS RULE                  |
+------------------------------------+----------------------------------------+
| Patient Anatomical Status          | Mandatory Hormone Therapy Regimen      |
+------------------------------------+----------------------------------------+
| INTACT UTERUS                      | Combined Estrogen + PROGESTIN          |
| (No prior hysterectomy)            | (Progestin protects endometrium from   |
|                                    | unopposed estrogen hyperplasia/cancer) |
+------------------------------------+----------------------------------------+
| PRIOR HYSTERECTOMY                 | ESTROGEN-ALONE (ET)                    |
| (Surgical removal of uterus)       | (No progestin needed; progestin adds   |
|                                    | breast cancer and cardiovascular risk) |
+------------------------------------+----------------------------------------+

• Rationale: Unopposed systemic estrogen stimulates endometrial stromal and epithelial proliferation, causing a 4- to 8-fold increase in endometrial hyperplasia and adenocarcinoma. Adding continuous or cyclic progestin (e.g., oral micronized progesterone 100–200 mg daily [Prometrium] or medroxyprogesterone acetate 2.5–5 mg daily [Provera], or bazedoxifene [SERM]) completely neutralizes this malignant risk.

Local vs. Systemic Therapy for Isolated GSM

When menopausal symptoms are strictly limited to Genitourinary Syndrome of Menopause (GSM)—such as vaginal dryness, dyspareunia, vulvar pruritus, and recurrent UTIs without vasomotor hot flashes—low-dose local vaginal estrogen is the definitive treatment of choice:

• Formulations: Vaginal estradiol cream (Estrace), vaginal estradiol tablets (Vagifem), or low-dose estradiol vaginal ring (Estring).
• Safety Profile: Produces minimal systemic absorption; therefore, co-administration of a progestin is NOT required in women with an intact uterus.

The "Timing Hypothesis" & The Window of Opportunity

Insights from the Women's Health Initiative (WHI) and subsequent consensus guidelines (NAMS/The Menopause Society) establish the timing hypothesis:

• Favorable Benefit-Risk Window: Initiating systemic MHT in women < 60 years of age or within 10 years of menopause onset carries a favorable safety profile, showing reductions in all-cause mortality, coronary heart disease progression, and osteoporotic fractures alongside symptom resolution.
• Unfavorable Risk Window: Initiating MHT in women ≥ 60 years of age or > 10 to 20 years post-menopause carries elevated risks of stroke, venous thromboembolism, coronary events, and dementia.
• Route Advantage: Transdermal estradiol patches and gels bypass hepatic first-pass metabolism, avoiding induction of prothrombotic clotting factors and sex hormone-binding globulin (SHBG), conferring a substantially lower risk of VTE and stroke compared to oral estrogens.

Non-Hormonal Pharmacotherapy for Vasomotor Symptoms

In women with contraindications to systemic estrogens (history of breast cancer, prior DVT/PE, stroke, MI, active liver disease, unexplained vaginal bleeding):

1. Fezolinetant (Veozah) 45 mg orally once daily: First-in-class non-hormonal Neurokinin 3 (NK3) receptor antagonist that directly blocks NKB binding on KNDy neurons in the hypothalamic thermoregulatory center, restoring normal temperature regulation. Safety Monitoring: Check baseline hepatic transaminases (ALT/AST), and monitor at 3, 6, and 9 months post-initiation (hepatotoxicity risk).
2. SSRIs & SNRIs: Paroxetine 7.5 mg daily (Brisdelle — only FDA-approved SSRI for VMS; avoid with tamoxifen due to strong CYP2D6 inhibition blocking conversion to active endoxifen), Venlafaxine ER 37.5–75 mg daily, Desvenlafaxine 50 mg daily.
3. Gabapentin: 300 to 900 mg daily at bedtime (highly effective for nocturnal hot flashes and associated insomnia).

5. Major Teratogenic Medications in Ambulatory Practice

Teratogens are chemical or environmental agents that induce abnormal structural or functional development in an embryo or fetus. Maternal physiological changes and critical embryonic organogenesis windows (Weeks 3 through 8 post-conception) make prospective medication reconciliation imperative.

Core Ambulatory Teratogens & Specific Fetal Anomalies

6. Lactation Pharmacology & Infant Drug Exposure

Most medications transfer into human breast milk to some degree via passive diffusion across the mammary alveolar epithelial membrane. The ambulatory care pharmacist must evaluate maternal drug therapy to maximize infant safety while supporting breastfeeding.

Pharmacokinetic Determinants of Milk Transfer

1. Relative Infant Dose (RID): The gold-standard clinical metric estimating infant drug exposure, calculated as the infant daily dose via milk (mg/kg/day) divided by the maternal daily dose (mg/kg/day), expressed as a percentage: $\text{RID (\%)} = \frac{\text{Infant Dose (mg/kg/day)}}{\text{Maternal Dose (mg/kg/day)}} \times 100$
   • The 10% Safety Rule: An RID < 10% is universally considered clinically safe for most therapeutic agents.
2. Maternal Protein Binding: Highly protein-bound drugs (> 90%, e.g., warfarin, ibuprofen, sertraline) have very low free unbound fractions in maternal plasma, resulting in negligible diffusion into milk.
3. Molecular Weight: Large macromolecules (> 800 to 1,000 Da, e.g., heparins, insulins, monoclonal antibodies like adalimumab) poorly cross the lipid bilayer into breast milk; furthermore, any ingested macromolecule is denatured and degraded within the infant GI tract.
4. Lipid Solubility & Ion Trapping: Breast milk has higher lipid content and a slightly lower pH (~7.0 to 7.2) than maternal plasma (pH 7.4). Weakly basic drugs can become ionized and trapped in milk.
5. Infant Oral Bioavailability: Drugs with poor gastrointestinal absorption (e.g., aminoglycosides, vancomycin) cannot enter the infant systemic circulation even if present in milk.

Critical Black Box Warnings & Absolute Lactation Contraindications

+-----------------------------------------------------------------------------+
|                   CRITICAL LACTATION WARNINGS & CONTRAINDICATIONS           |
+------------------------------------+----------------------------------------+
| Medication Class / Agent           | Clinical Mechanism & Infant Risk       |
+------------------------------------+----------------------------------------+
| Codeine & Tramadol                 | FDA BOXED WARNING: Maternal CYP2D6     |
|                                    | ultra-rapid metabolism produces rapid, |
|                                    | massive morphine accumulation in milk; |
|                                    | causes fatal infant respiratory arrest |
+------------------------------------+----------------------------------------+
| Amiodarone                         | Massive iodine content and 50-day t1/2 |
|                                    | cause infant hypothyroidism & goiter   |
+------------------------------------+----------------------------------------+
| Radioactive Iodine (I-131)         | Concentrates in breast milk; destroys  |
|                                    | infant thyroid gland (Stop nursing)    |
+------------------------------------+----------------------------------------+
| Antineoplastic Chemotherapy        | Cellular cytotoxicity & bone marrow    |
|                                    | suppression in infant                  |
+------------------------------------+----------------------------------------+
| Ergotamines & Pseudoephedrine      | Suppress prolactin, abolishing milk    |
|                                    | production; ergotism in infant         |
+------------------------------------+----------------------------------------+

Preferred First-Line Regimens in Lactation: For analgesia, ibuprofen (RID ~0.6%) and acetaminophen (RID ~2%) are preferred over opioids. For hypertension, labetalol, nifedipine, and enalapril exhibit negligible milk excretion and are favored. Authoritative information must be referenced via the NIH LactMed Database.